NIH-CSR <script type="text/javascript"> var wmNotice = "UNT Web Archive - External links, forms, and search boxes may not function within this collection. Url: http://cms.csr.nih.gov/PeerReviewMeetings/CSRIRGDescription/AARRIRG/ADDT.htm time: 14:49:18 Sep 20, 2008"; var wmHideNotice = "hide"; var contextRoot = "https://webarchive.library.unt.edu/eot2008/"; </script> <script type="text/javascript" src="https://webarchive.library.unt.edu/eot2008/js/disclaim.js"></script> <span id="Postingname3_PostingDisplayName">AIDS Discovery and Development of Therapeutics Study Section [ADDT] (Formerly AARR-3)</span> (AARRIRG)


search

AIDS Discovery and Development of Therapeutics Study Section [ADDT] (Formerly AARR-3)

[ADDT Roster]

The AIDS Discovery and Development of Therapeutics [ADDT] Study Section reviews applications concerned with the design, discovery, and development of therapeutics for HIV/AIDS. The science encompassed includes preclinical development of gene-based therapeutics and diagnostics, traditional drugs, targeted drug design and modeling based on structure, pharmacology, toxicology, drug delivery, and assays to measure drug/therapeutic levels. This Study Section also reviews applications related to the development of vector and cellular aspects/components of gene-based and immune reconstitution therapies for HIV/AIDS, viral resistance, and interactions of drugs/therapeutics used to treat/prevent HIV infection and associated complications, as well as other used/abused agents.

Specific areas covered by ADDT:

Development of targeted screens for discovery of new anti-HIV agents
Isolation and characterization of natural products as therapeutics/preventives for opportunistic infections
Preclinical development of therapies for HIV/AIDS, AIDS-associated opportunistic infections, and cancers [including toxicology and pharmacology]
Design and development of vectors for targeted delivery to cells and tissues, and for in vivo use
Preclinical evaluation of gene-based therapies [e.g., ribozymes, trans- dominant inhibitors, anti-sense and si-RNA]
Mechanisms of drug resistance
Assay development for molecular-based measures of resistance, therapeutic efficacy, and effects of therapy on immune parameters
Chemistry, pharmacology, and biochemistry of target compounds for HIV and AIDS-associated opportunistic infections
Studies of drug-drug interactions

ADDT has the following shared interests within the AARR IRG:

Studies dealing with mechanism of action, regulation, and means of interaction of viral genes and/or gene products with host factors are reviewed by AMCB, whereas ADDT reviews applications that use this information for assays and screens in therapeutics discovery.
ADDT shares interest with AOIC in studies of AIDS-associated opportunistic infections. ADDT reviews targeted screening, natural products isolation, and characterization and drug development after anti-microbial/viral activity has been established, whereas AOIC covers the microbiology of the opportunistic infections, especially their pathogenesis.